Literature DB >> 32719037

Predictive model of increased mortality and bed occupancy if thrombolysis becomes the initial treatment strategy for STEMI during the SARS-CoV-2 pandemic.

Luke Dancy1, Kevin O'Gallagher2, Matthew Ryan3, Philip A MacCarthy1, Ajay M Shah3.   

Abstract

During the current SARS-CoV-2 pandemic the restructure of healthcare services to meet the huge increase in demand for hospital resource and capacity has led to the proposal that where necessary ST elevation myocardial infarction (STEMI) could be managed by intravenous thrombolysis in the first instance as a means of reducing the workforce requirements of a primary angioplasty service run at a heart attack centre. Our modelling, based on data from the UK, shows that contrary to reducing demand, the effect on both mortality and bed occupancy would be negative with 158 additional deaths per year for each 10% reduction in primary angioplasty and at a cost of ~8,000 additional bed days per year for the same reduction. Our analysis demonstrates that specialist services such as heart attack pathways should be protected during the COVID crisis to maximise the appropriate use of resource and prevent unnecessary mortality. © Royal College of Physicians 2020. All rights reserved.

Entities:  

Keywords:  COVID-19; STEMI; primary PCI; thrombolysis

Mesh:

Year:  2020        PMID: 32719037      PMCID: PMC7539733          DOI: 10.7861/clinmed.2020-0293

Source DB:  PubMed          Journal:  Clin Med (Lond)        ISSN: 1470-2118            Impact factor:   2.659


  10 in total

Review 1.  Coronary Disease: Acute myocardial infarction: failed thrombolysis.

Authors:  M A de Belder
Journal:  Heart       Date:  2001-01       Impact factor: 5.994

2.  The variability of critical care bed numbers in Europe.

Authors:  A Rhodes; P Ferdinande; H Flaatten; B Guidet; P G Metnitz; R P Moreno
Journal:  Intensive Care Med       Date:  2012-07-10       Impact factor: 17.440

3.  Hospital length of stay and clinical outcomes in older STEMI patients after primary PCI: a report from the National Cardiovascular Data Registry.

Authors:  Rajesh V Swaminathan; Sunil V Rao; Lisa A McCoy; Luke K Kim; Robert M Minutello; S Chiu Wong; David C Yang; Paramita Saha-Chaudhuri; Harsimran S Singh; Geoffrey Bergman; Dmitriy N Feldman
Journal:  J Am Coll Cardiol       Date:  2015-03-31       Impact factor: 24.094

4.  Critical Care Utilization for the COVID-19 Outbreak in Lombardy, Italy: Early Experience and Forecast During an Emergency Response.

Authors:  Giacomo Grasselli; Antonio Pesenti; Maurizio Cecconi
Journal:  JAMA       Date:  2020-04-28       Impact factor: 56.272

Review 5.  Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials.

Authors:  Ellen C Keeley; Judith A Boura; Cindy L Grines
Journal:  Lancet       Date:  2003-01-04       Impact factor: 79.321

6.  Impact of COVID-19 pandemic on patients with ST-segment elevation myocardial infarction: Insights from a British cardiac center.

Authors:  Hesham K Abdelaziz; Amr Abdelrahman; Amjad Nabi; Maciej Debski; Amgad Mentias; Tawfiq Choudhury; Billal Patel; Marwan Saad
Journal:  Am Heart J       Date:  2020-05-11       Impact factor: 4.749

7.  Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.

Authors:  Nanshan Chen; Min Zhou; Xuan Dong; Jieming Qu; Fengyun Gong; Yang Han; Yang Qiu; Jingli Wang; Ying Liu; Yuan Wei; Jia'an Xia; Ting Yu; Xinxin Zhang; Li Zhang
Journal:  Lancet       Date:  2020-01-30       Impact factor: 79.321

8.  Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study.

Authors:  Matthew J Cummings; Matthew R Baldwin; Darryl Abrams; Samuel D Jacobson; Benjamin J Meyer; Elizabeth M Balough; Justin G Aaron; Jan Claassen; LeRoy E Rabbani; Jonathan Hastie; Beth R Hochman; John Salazar-Schicchi; Natalie H Yip; Daniel Brodie; Max R O'Donnell
Journal:  Lancet       Date:  2020-05-19       Impact factor: 79.321

Review 9.  The Obstacle Course of Reperfusion for ST-Segment-Elevation Myocardial Infarction in the COVID-19 Pandemic.

Authors:  Marco Roffi; Giulio Guagliumi; Borja Ibanez
Journal:  Circulation       Date:  2020-04-21       Impact factor: 29.690

10.  Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers are not associated with severe COVID-19 infection in a multi-site UK acute hospital trust.

Authors:  Daniel M Bean; Zeljko Kraljevic; Thomas Searle; Rebecca Bendayan; O'Gallagher Kevin; Andrew Pickles; Amos Folarin; Lukasz Roguski; Kawsar Noor; Anthony Shek; Rosita Zakeri; Ajay M Shah; James T H Teo; Richard J B Dobson
Journal:  Eur J Heart Fail       Date:  2020-07-07       Impact factor: 17.349

  10 in total
  1 in total

1.  COVID-19 and changes in activity and treatment of ST elevation MI from a UK cardiac centre.

Authors:  Yang Chen; Krishnaraj S Rathod; Stephen Hamshere; Fizzah Choudry; Mohammed M Akhtar; Miles Curtis; Rajiv Amersey; Oliver Guttmann; Constantinos O'Mahony; Ajay Jain; Andrew Wragg; Andreas Baumbach; Anthony Mathur; Daniel A Jones
Journal:  Int J Cardiol Heart Vasc       Date:  2021-02-23
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.